EPHA6 (EPH Receptor A6)

News alerts, weekly reports and conference planners

over1year

Clinicopathological analysis of gastric adenocarcinoma with elevated serum alpha-fetoprotein and enteroblastic differentiation (PubMed, Zhonghua Zhong Liu Za Zhi)

TP53 mutation is the most common type of gene mutation. In addition, some cases are accompanied by HER2 amplification and gene rearrangement.

over 1 year ago

Journal • IO biomarker

HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR3 (Fibroblast growth factor receptor 3) • CCNE1 (Cyclin E1) • LRP1B (LDL Receptor Related Protein 1B) • ATRX (ATRX Chromatin Remodeler) • AFP (Alpha-fetoprotein) • CLDN6 (Claudin 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • GPC3 (Glypican 3) • IRS2 (Insulin receptor substrate 2) • SOX2 • GNAS (GNAS Complex Locus) • MME (Membrane Metalloendopeptidase) • CDX2 (Caudal Type Homeobox 2) • SALL4 (Spalt Like Transcription Factor 4) • EPHA5 (EPH Receptor A5) • EPHB1 (EPH Receptor B1) • GATA3 (GATA binding protein 3) • EPHA6 (EPH Receptor A6) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)

over1year

A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets. (PubMed, Front Oncol)

This particular gene exhibited links with immune infiltration subtypes and clinicopathologic parameters, holding promise as a valuable biomarker for predicting prognosis and responsiveness to immunotherapy in patients with KIRP. By meticulously scrutinizing the panorama of EphA genes in a spectrum of cancers, this study supplemented a complete map of the effect of EphA family in Pan-cancer and suggested that EphA family may be a potential target for cancer therapy.

over 1 year ago

Journal • IO biomarker • Pan tumor

EPHA3 (EPH receptor A3) • EPHA5 (EPH Receptor A5) • EPHA6 (EPH Receptor A6)

2years

Engineered Recombinant EGFP-Azurin Theranostic Nanosystem for Targeted Therapy of Prostate Cancer. (PubMed, Mol Pharm)

This was achieved by specifically targeting EphA6 receptors overexpressed on the cancer cell surface via C-terminal peptide, azu (80-128). Herein, we report antiproliferative, apoptotic, antimigratory, and anti-invasive effects of this nanosystem on LNCaP cells, while having no similar effects on EphA6 negative human normal lung cells, WI-38.

2 years ago

Journal

EPHA6 (EPH Receptor A6)

3years

The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer. (PubMed, Cancer Chemother Pharmacol)

Overall, the SNPs examined in the study did not influence return-to-work or stable labor market attachment after breast cancer in premenopausal women. Our findings did suggest that the outcomes were delayed in homozygote carriers of CYP3A5 rs776746, though the number of homozygotes was low.

3 years ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • GSTP1 (Glutathione S-transferase pi 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • EPHA5 (EPH Receptor A5) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • EPHA6 (EPH Receptor A6)

docetaxel • cyclophosphamide

3years

Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients. (PubMed, Acta Med Okayama)

There was no significant correlation of CIPN with any other SNP. A multivariate analysis showed that the cumulative dose of nab-PTX was most strongly correlated with CIPN (p<0.01).

3 years ago

P2 data • Journal • Metastases

HER-2 (Human epidermal growth factor receptor 2) • EPHA5 (EPH Receptor A5) • EPHA6 (EPH Receptor A6)

HER-2 negative

albumin-bound paclitaxel

over3years

ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. (PubMed, Int J Cancer)

Molecularly targeted treatment with crizotinib induced a rapid and sustained partial response...In summary, the high prevalence of GOPC-ROS1 and noncanonical ROS1 fusions pose diagnostic challenges. We advocate NGS-based comprehensive molecular profiling of MSS CRCs that are wild type for RAS and BRAF and patient enrollment in precision trials.

over 3 years ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EPHA6 (EPH Receptor A6) • MCM9 (Minichromosome Maintenance 9 Homologous Recombination Repair Factor) • SRPK1 (SRSF Protein Kinase 1)

KRAS mutation • ROS1 fusion • ROS1 rearrangement • KRAS Q61H • ROS1 wild-type

Xalkori (crizotinib)

over3years

Pharmacogenetics of Taxane-Induced Neurotoxicity in Breast Cancer: Systematic Review and Meta-Analysis. (PubMed, Clin Transl Sci)

In conclusion, through systematic review and meta-analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making.

over 3 years ago

Retrospective data • Review • Journal

BCL6 (B-cell CLL/lymphoma 6) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • GSTP1 (Glutathione S-transferase pi 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • EPHA5 (EPH Receptor A5) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • EPHA6 (EPH Receptor A6)

GSTP1 rs1138272